Key result
Current use of rofecoxib (OR 1.71; 95% CI 1.33-2.18) and etoricoxib (OR 2.38; 95% CI 1.10-5.13), but not celecoxib, was associated with a significantly increased risk of ischemic stroke.
Why the study?
Does the use of COX-2 selective NSAIDs increase the risk of ischemic stroke in patients prescribed NSAIDs?
Case-Control (n=14,953)
Yes
Does the use of COX-2 selective NSAIDs increase the risk of ischemic stroke in patients prescribed NSAIDs?
Odds Ratio: 1.71 (95% CI 1.33–2.18)
Rofecoxib and etoricoxib, but not celecoxib, are associated with an increased risk of ischemic stroke, suggesting differing cerebrovascular safety profiles among COX-2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Supports variable stroke risk among COX-2 inhibitors; leaves open clinical implications pending randomized confirmation.
Andersohn et al. (2006) conducted a case-control in Ischemic stroke (n=14,953). COX-2 selective NSAIDs (rofecoxib, etoricoxib, celecoxib) vs. Matched controls was evaluated on Ischemic stroke (OR 1.71, 95% CI 1.33 to 2.18). Current use of rofecoxib (OR 1.71; 95% CI 1.33-2.18) and etoricoxib (OR 2.38; 95% CI 1.10-5.13), but not celecoxib, was associated with a significantly increased risk of ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: